SEARCH

SEARCH BY CITATION

References

  • 1
    Wasmuth HE, Stolte C, Geier A et al. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004; 4: 4.
  • 2
    Garrido Palma G, Sánchez Cuenca JM, Olaso V et al. Response to treatment with interferon-alfa in patients with chronic hepatitis C and high titers of -M2, -M4 and -M8 antimitochondrial antibodies. Rev Esp Enferm Dig 1999; 91: 168181.
  • 3
    Yee LJ, Kelleher P, Goldin RD et al. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat 2004; 11: 459464.
  • 4
    Narciso-Schiavon JL, Freire FC, Suarez MM et al. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? Eur J Gastroenterol Hepatol 2009; 21: 440446.
  • 5
    Chen CH, Lee CM, Chen CH et al. Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C. Chang Gung Med J 2010; 33: 258265.
  • 6
    Williams MJ, Lawson A, Neal KR, Ryder SD, Irving WL; Trent HCV Group. Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat 2009; 16: 325331.
  • 7
    Muratori P, Muratori L, Guidi M et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005; 40: 501507.
  • 8
    Bai L, Feng ZR, Lu HY, Li WG, Yu M, Xu XY. Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China. Chin Med J (Engl) 2009; 122: 59.
  • 9
    Ferri S, Muratori L, Quarneti C et al. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. J Hepatol 2009; 50: 10931101.
  • 10
    Monti V, Aghemo A, Rumi MG, Donato MF, Del Ninno E, Colombo M. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies. Antivir Ther 2005; 10: 715720.
  • 11
    Duclos-Vallée JC, Nishioka M, Hosomi N et al. Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection. J Hepatol 1998; 28: 965970.
  • 12
    Cassani F, Cataleta M, Valentini P et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26: 561566.
  • 13
    Todros L, Saracco G, Durazzo M et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995; 22: 13741378.
  • 14
    Sarrazin C, Berg T, Ross RS et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48: 289351.
  • 15
    Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999; 31(Suppl 1): 3942.